All canine diagnoses

Your dog was diagnosed with Splenic Hemangiosarcoma (Stage I–II). Accounts for 5–7% of all canine tumours; 25–100× higher incidence in dogs than humans. Most common splenic malignancy. Often presents as emergency haemoabdomen. Compare 8 treatment options for dogs including Splenectomy Alone, Splenectomy + Single-Agent Doxorubicin, Splenectomy + Single-Agent Carboplatin — with survival times, costs, and what to expect during treatment.

🐕

Splenic Hemangiosarcoma (Stage I–II)

Stage I (confined to spleen) – Stage II (ruptured with regional involvement)

BreedsGolden RetrieverGerman Shepherd DogPortuguese Water DogBernese Mountain DogFlat-Coated RetrieverBoxerSkye TerrierLabrador Retriever
canine

Mesenchymal

About This Cancer

Hemangiosarcoma is an aggressive cancer arising from the cells that line blood vessels (vascular endothelium). In the spleen, it forms blood-filled tumours that can rupture without warning, causing life-threatening internal bleeding (haemoabdomen) — this emergency presentation is often the first sign of the disease. Stage I–II means the tumour is confined to the spleen without visible distant spread, though microscopic metastatic disease is presumed present in the vast majority of cases at diagnosis. Large and giant breeds, particularly Golden Retrievers and German Shepherd Dogs, are at highest risk. Even after surgical removal of the spleen, the cancer has almost always begun spreading microscopically, which is why follow-up chemotherapy is strongly recommended to delay the growth of these tiny secondary deposits.

Clinical Staging System for Canine Splenic HSA

Based on tumour confinement to spleen, rupture status, and presence of metastasis.

Stage ITumour confined to spleen; no rupture; no metastasis
Stage IIRuptured splenic tumour with regional peritoneal involvement or lymph node metastasis, but no distant metastasis
Stage IIIDistant metastasis present (liver, lung, omentum, other organs)
Prognostic Factors(3)
Stage at diagnosisStage I MST 196 days vs Stage II 117 days vs Stage III 23 days with surgery alone. Most important prognostic factor.(Wendelburg et al., 2015)
Age at diagnosisDogs <6 years at diagnosis have significantly better chemotherapy response; 15% achieve 2+ year survival with doxorubicin. Older dogs have poorer response.(PRO-DOX Study, 2025)
Completion of chemotherapy protocolDogs completing ≥3 cycles of chemotherapy: MST ~200 days vs <55 days for those completing <3 cycles.(del Castillo et al., 2025)
Minimum Workup(9 steps)
1Complete blood count with manual differential
2Serum biochemistry panel
3Coagulation panel (PT, aPTT, fibrinogen, D-dimers — assess for DIC)
4Urinalysis
5Three-view thoracic radiographs (metastasis screening)
6Abdominal ultrasound
7Echocardiography (rule out concurrent cardiac HSA)
8Blood typing / crossmatch if anaemic and transfusion anticipated
9Histopathology of excised spleen (definitive diagnosis requires tissue)

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Splenectomy Alone
~2.5 mo (1.6–3)
Splenectomy + Single-Agent Doxorubicin
~6 mo (5–9)
Splenectomy + Single-Agent Carboplatin
~5 mo (4–7)
Splenectomy + AC Protocol (Doxorubicin + Cyclophosphamide)
~6.5 mo (3–8)
Splenectomy + VAC Protocol (Vincristine, Doxorubicin, Cyclophosphamide)
~6 mo (5–6.3)
Splenectomy + Metronomic Chemotherapy
~5.9 mo (4–6)
Comfort Care / Palliation
~1.5 mo (0.5–3)
Splenectomy + Doxorubicin + Metronomic Maintenance
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.